New paradigms for treatment-resistant depression-Reference-Cited by-同舟云学术

New paradigms for treatment-resistant depression

Published:2013-07 Issue:1 Volume:1292 Page:21-31
ISSN:0077-8923
Container-title:Annals of the New York Academy of Sciences
language:en
Short-container-title:Ann. N.Y. Acad. Sci.

Author:

Zarate Carlos¹,Duman Ronald S.²,Liu Guosong³,Sartori Simone⁴,Quiroz Jorge⁵,Murck Harald

Affiliation:

1. Experimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health; National Institutes of Health, and Department of Health and Human Services; Bethesda; Maryland

2. Department of Psychiatry and Neurobiology; Yale University School of Medicine; New Haven; Connecticut

3. Tsinghua-Peking Center for Life Sciences, School of Medicine; Tsinghua University; Beijing; China

4. Department of Pharmacology and Toxicology; University of Innsbruck; Innsbruck; Austria

5. Child and Adult Psychiatry; Neuroscience Translational Medicine, Roche; Nutley; New Jersey

Publisher

Wiley

Subject

History and Philosophy of Science,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/nyas.12223/fullpdf

Reference50 articles.

1. Amantadine in depression;Vale;Lancet,1971

2. Glutamate and depression: clinical and preclinical studies;Paul;Ann. N. Y. Acad. Sci.,2003

3. The glutamate story;Watkins;Br. J. Pharmacol.,2006

4. The catecholamine hypothesis of affective disorders: a review of supporting evidence;Schildkraut;Am. J. Psychiatry,1965

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Group-Based Symptom Trajectory of Intramuscular Administration of Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder: A Post-Hoc Analysis;Neuropsychiatric Disease and Treatment;2023-05

2. A unique case of very low‐dose subcutaneous ketamine use: Maintenance option of ketamine for treatment‐resistant depression;Clinical Case Reports;2022-12

3. Drosophila HisT is a specific histamine transporter that contributes to histamine recycling in glia;Science Advances;2022-10-28

4. Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial;Frontiers in Psychiatry;2022-07-22

5. Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants;Biochemical and Biophysical Research Communications;2022-02